default author photo

Christopher A. Lamb

Newcastle University

Newcastle upon Tyne

NE1 7RU

United Kingdom

Newcastle Upon Tyne Hospitals NHS Foundation Trust

SCHOLARLY PAPERS

1

DOWNLOADS

112

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)

Number of pages: 40 Posted: 21 Sep 2022
Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Institute of Biomedical and Clinical Science, Newcastle University, Government of the United Kingdom - Department of Gastroenterology, Barts Health NHS Trust - Department of Gastroenterology, NHS Lothian - Department of Gastroenterology, Imperial College London - Department of Immunology and Inflammation, St Marks Hospital and Academic Institute - Department of Gastroenterology, Imperial College London, Imperial College London - Department of Infectious Disease, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology and Imperial College London - Department of Metabolism, Digestion and Reproduction
Downloads 112 (630,858)

Abstract:

Loading...

SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, thiopurine, azathioprine, anti-TNF therapy, infliximab, vedolizumab, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, mRNA1273, breakthrough infection, Omicron, BA.4/5